Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
Recommend :
React to this article
Latest news on ASTRAZENECA PLC
6h ago FTSE steadies near two-month high, Anglo American up
8h ago EXCLUSIVE : 'Back to normal' for AstraZeneca CEO, despite Pfizer rumors
10h ago ASTRAZENECA : New data indicates Brilinta/Brilique has the flexibility to be ini..
1d ago Pricing is key for new heart drugs challenging cheap generics
1d ago UK fund star Woodford dumps HSBC on banking fine inflation fears
1d ago ASTRAZENECA : Study Shows Flexibility Of Brilinta/Brilique Treatment
1d ago ASTRAZENECA : New data indicates Brilinta/Brilique™ has the flexibility to..
4d ago S&P 500 edges up to set new record; best month since Feb
4d agoDJEuropean Stocks See Cautious Rebound -- 2nd Update
4d agoDJEuropean Stocks See Cautious Rebound -- Update
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
AstraZeneca plc : Income Statement Evolution
More Financials
Dynamic quotes